On the whole, an improved lipid profile and lower risk of CAD in ANGPTL8 PTV carriers compared to noncarriers lends support to the efficacy of an antibody-based inhibition of ANGPTL8 in treating dyslipidemia and CAD. This evidence concerns the gene ANGPTL8 and coronary artery disorder.